TVTX
Travere Therapeutics, Inc.
September 15, 2026 · market open
- Rarity
- 1.61
- Peak move
- −6.54%
- Float cap
- $5.9B
Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies for people with rare kidney and metabolic diseases. It commercializes FILSPARI (sparsentan) for adults with primary IgAN at risk of disease progression, and is developing sparsentan for FSGS and pegtibatinase for HCU.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the movepatent_eventThe USPTO issued a notice of allowance for a Travere Therapeutics patent application covering methods of using sparsentan (FILSPARI) to treat IgA nephropathy, which upon grant would extend method protection to 2037, with a similar FSGS patent application pending.
executive_remarkAt Cantor Fitzgerald's 12th Annual Global Healthcare Conference, Travere CFO Chris Cline and CCO Peter Heerma said FILSPARI exceeded launch expectations and remains the most-prescribed novel IgA nephropathy medicine, reiterated over $3 billion in peak sales potential, cited addressable patient populations, discussed patent protection and planned regulatory engagement on civorebrutinib, and reaffirmed Phase 3 HARMONY pegtibatinase topline in 2H 2027.
insider_saleTravere Therapeutics director Jeffrey A. Meckler sold 14,000 shares on September 10, 2026, one of six insider transactions reported on September 11, 2026.
reg_fd_disclosureOn September 10, 2026, Travere Therapeutics' Compensation Committee granted inducement equity awards to 16 new employees covering 56,220 restricted stock units under Nasdaq Listing Rule 5635(c)(4).
institutional_flowAllianz Asset Management disclosed a new 42,966-share Travere Therapeutics position worth about $2.44 million in its second-quarter 13F, while CalSTRS raised its stake by 5,062.4% to 5,427,287 shares valued at roughly $308.3 million.